Teva Pharmaceutical Industries has obtained final FDA approval for fluoxetine, a generic version of Eli Lilly and Co.'s Sarafem Pulvules, as a treatment for premenstrual dysphoric disorder. Teva also gets a 180-day marketing exclusivity period for being the first to submit an abbreviated new drug application for the medication.

Related Summaries